Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
NCT05644561Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Started Jun 2023; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05644561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644561.